Genetic testing in hypertrophic cardiomyopathy: for all or just selected patients?

13 May 2024 (16:00 - 16:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Adriana Fonseca Vazao

Leiria Hospital Centre, Leiria (Portugal)

6 More presentations in this session

Presentation thumbnail

Are sodium-glucose co-transporter 2 inhibitors safe in hypertrophic cardiomyopathy?

Doctor V. Biletska (Kharkiv, UA)

Abstract Slides Video

Presentation thumbnail

Hypertrophic cardiomyopathy phenotype and the importance of systemic inflammation

Doctor I. Miranda (Amadora, PT)

Abstract Slides Video

Presentation thumbnail

Could we use cardiopulmonary exercise test to distinguish hypertrophic cardiomyopathy from Fabry disease? New insights from Italy

Doctor F. Re (Roma, IT)

Abstract Slides Video

Presentation thumbnail

Design of ODYSSEY-HCM: a phase 3 randomized placebo-controlled study to assess the efficacy and safety of mavacamten in patients with nonobstructive hypertrophic cardiomyopathy

Doctor I. Olivotto (Florence, IT)

Abstract Slides Video

Presentation thumbnail

Is the mortality of chronic chagas cardiomyopathy higher than cardiomyopathy due to other etiologies? A systematic review and meta-analysis

Doctor L. Echeverria (Floridablanca, CO)

Abstract Slides Video

Access the full session

Session thumbnail

Myocardial disease - clinical 9

The Event

Event poster

Heart Failure 2024

13 May 2024 16:00 CET

You may be interested in

Congress Presentation

Clinical features and prognosis according to genotype variation in hypertrophic cardiomyopathy

Congress Presentation

Genotype-driven prognostication in dilated cardiomyopathy

Congress Presentation

Identification of a novel actin gene mutation, ACTC1 p.Asn94Ile, in a family with cardiomyopathy and conduction disease

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources